Filter Results:
(338)
Show Results For
- All HBS Web (338)
- Faculty Publications (228)
Show Results For
- All HBS Web (338)
- Faculty Publications (228)
- June 2014 (Revised September 2014)
- Case
Johnson & Johnson: The Promotion of Wellness
By: John A. Quelch and Carin-Isabel Knoop
To create the world's healthiest workforce, diversified health care giant Johnson & Johnson (J&J) mandated participation in its "Culture of Health" program globally, customized by location, culture, and specific health needs to offer prevention-focused education,... View Details
Keywords: Healthcare; Employee Motivation; Transformation; Ethics; Health; Human Resources; Leadership; Management; Personal Development and Career; Problems and Challenges; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Middle East; Latin America; Europe; Asia
Quelch, John A., and Carin-Isabel Knoop. "Johnson & Johnson: The Promotion of Wellness." Harvard Business School Case 514-112, June 2014. (Revised September 2014.)
- 10 Aug 2015
- Research & Ideas
New Medical Devices Get To Patients Too Slowly
While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of medical devices. Instead of... View Details
- 13 Oct 2009
- Research & Ideas
7 Lessons for Navigating the Storm
results—the next quarterly report and the rewards that come from short-term success—while ignoring their responsibilities to sustaining and building the company's long-term fiscal health. Ironically, it was the Wall Street leaders who put so much pressure on corporate... View Details
Keywords: by Martha Lagace
- 15 Jun 2007
- Research & Ideas
Remembering Alfred Chandler
Chemical and Pharmaceutical Industries. In his lifetime, he produced a range of books, edited collections, and articles covering railways, management, global competition, anthracite coal, the career of Alfred P. Sloan, the nature of... View Details
Keywords: by Sean Silverthorne
- January 2014 (Revised June 2015)
- Case
Amgen Inc.: Pursuing Innovation and Imitation? (A)
By: Ian W. Mackenzie
Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:... View Details
Mackenzie, Ian W. "Amgen Inc.: Pursuing Innovation and Imitation? (A)." Harvard Business School Case 714-424, January 2014. (Revised June 2015.)
- September–October 2020
- Article
Social-Impact Efforts That Create Real Value
By: George Serafeim
Until the mid-2010s few investors paid attention to environmental, social, and governance (ESG) data—information about companies’ carbon footprints, labor policies, board makeup, and so forth. Today the data is widely used by investors. How can organizations create... View Details
Keywords: Sustainability; Sustainability Management; ESG; ESG (Environmental, Social, Governance) Performance; ESG Disclosure; ESG Disclosure Metrics; ESG Ratings; ESG Reporting; Social Impact; Impact Measurement; Social Innovation; Purpose; Corporate Purpose; Corporate Social Responsibility; Strategy; Social Enterprise; Society; Accounting; Investment; Environmental Sustainability; Climate Change; Corporate Strategy; Mission and Purpose; Corporate Social Responsibility and Impact; Financial Services Industry; Chemical Industry; Technology Industry; Consumer Products Industry; Pharmaceutical Industry; North America; Europe; Japan; Australia
Serafeim, George. "Social-Impact Efforts That Create Real Value." Harvard Business Review 98, no. 5 (September–October 2020): 38–48.
- Web
2024 Reunion Presentations - Alumni
market? How are jobs affected as AI penetrates the workplace? What are the long-term consequences of COVID-19 on the workforce? What is the explanation for America having a record number of job openings and near record-low workforce... View Details
- September 2013 (Revised August 2015)
- Background Note
Leadership and Teaming
By: Ethan Bernstein
Small differences in the leadership of teams can have large consequences for the success of their efforts. Many initiatives fail not because of a fatal error in judgment or insufficient ideas, knowledge, motivation, or capabilities to deliver a solution. They fail... View Details
Keywords: Teams; Teaming; Leadership And Managing People; Leadership; Team Effectiveness; Team Performance; Team Design; Team Leadership; Teamwork; Team Process; Team Function; Team Launch; 60/30/10 Rule; Team Boundary; Distribution Of Leadership Authority; Self-Managed Teams; Virtual Teams; Unbounded Teams; Acts Of Leadership; Execution Teams; Decision Making Teams; Creativity Teams; Team Size; Task Design; Team Timeline; Team Roles; Team Representation; Diversity; Team Familiarity; Collective Intelligence; Team Stages Of Development; Team Coaching; Performance Pressure; X-Teams; Team Focus; Interaction; Management Teams; Managerial Roles; Management Systems; Management Style; Management Skills; Management Practices and Processes; Organizational Design; Organizational Structure; Performance Effectiveness; Performance Efficiency; Performance Productivity; Groups and Teams; Networks; Social Psychology; Behavior; Conflict and Resolution; Creativity; Social and Collaborative Networks; Satisfaction; Prejudice and Bias; Power and Influence; Personal Characteristics; Familiarity; Cognition and Thinking; Attitudes; Projects; Organizational Culture; Organizational Change and Adaptation; Leadership Development; Leadership Style; Leading Change; Knowledge Use and Leverage; Knowledge Sharing; Collaborative Innovation and Invention; Innovation and Management; Innovation Leadership; Design; Interpersonal Communication; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Asia; North and Central America; South America; Atlantic Ocean; Central Asia; Europe; Latin America; Middle East; Oceania; West Indies
Bernstein, Ethan. "Leadership and Teaming." Harvard Business School Background Note 414-033, September 2013. (Revised August 2015.)
- May 2020 (Revised March 2022)
- Case
The Coronavirus (COVID-19) Pandemic and the Global Economy (A)
By: Alberto Cavallo and Christian Godwin
In April 2020, the world struggled to contain the exponential escalation of the coronavirus (COVID-19) pandemic. Dozens of countries had imposed restrictions on travel, work, and social gatherings. A large share of the global population was under lockdowns and... View Details
Keywords: COVID-19 Pandemic; Demand and Consumers; Supply and Industry; Finance; Central Banking; Financial Markets; International Finance; Globalization; Government and Politics; Health Pandemics; Decision Making; Macroeconomics; Employment; Crisis Management; Supply Chain; Risk and Uncertainty; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Asia; China; Europe; Latin America; Africa; United States
Cavallo, Alberto, and Christian Godwin. "The Coronavirus (COVID-19) Pandemic and the Global Economy (A)." Harvard Business School Case 720-031, May 2020. (Revised March 2022.)
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
pharmaceutical companies in 1984, American Home Products ranked first in sales and twenty-eighth in R&D expenditures as a percentage of sales.23 As the historian Williams Haynes noted, by the end of the 1930s, American Home Products... View Details
- Portrait Project
Mickey Millar
roach. Each incident left a stain on my spirit. While studying social welfare at HKS, I worked part-time so my pregnant sister wouldn't become homeless after she lost her job while on bed rest. During pharmaceutical case discussions at... View Details
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
Moderna, a pharmaceutical company, announced in September 2020 that it would slow enrollment of its COVID-19 vaccine trials to better improve representation. The majority of study participants were white, although COVID-19 was... View Details
- Profile
Thomas Grenier
friend raised 60,000 and climbed Cho-Oyu, which is near Mt. Everest in Tibet. In the summer of 2007, Thomas took a break from his McKinsey consulting position to attempt Gasherbrum IV, a summit that remains unreached. New heights in View Details
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
was not. The Economist reported at the time that there were many warning flags of the EC's intent to scuttle the deal. For some time, the magazine pointed out, a philosophical gap had been widening between Europe and America over the... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 01 Feb 2002
- News
Health Industry Alumni Convene for Conference
and CEO of Mediconsulting, Inc., spoke about creating a better model for business collaborations between biotech and pharmaceutical firms. Said Klietmann, the conference's biotechnology chair and a lecturer in pathology at Harvard Medical... View Details
- 01 Mar 2009
- News
A New Approach to Health-Care Reform
approach not just to insurance and reimbursement, but also to the places where medical services are delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
"Bank of America is interested in accessing innovative digital technologies that will help it redefine how banking is done," Sato says. "The bank sees this as an opportunity to fuel its continued competitive presence in a... View Details
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs what kinds of services. These things are all connected, and changing one piece, or plugging an... View Details
- 01 Dec 2004
- News
Finding a Balance
Do the rules of business change when a company’s product holds the power of life or death over its customers? That’s a question students must consider when discussing “Cipla,” a case about a $325 million Indian pharmaceutical company that... View Details
- 01 Dec 2013
- News
Your Own Medicine
to the trade group Pharmaceutical Research and Manufacturers of America (PhRMA), only one of 5,000 to 10,000 experimental compounds make it to FDA approval, and just 2 of the 10 that get that approval... View Details